Response time and safety profile of pulsed oral methotrexate therapy in idiopathic retinal periphlebitis

European Journal of Ophthalmology

Volumn 15, Issue 3, 2005, Pages 374-378

  Bali, T ^a   Saxena, Sandeep ^a,b   Kumar, D ^a   Nath, R ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b G 19 River Bank Colony   (India)

Author keywords

Eales' disease; Methotrexate; Pulsed therapy; Retinal periphlebitis

Indexed keywords

METHOTREXATE;

ADULT; ANOREXIA; ARTICLE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HUMAN; IDIOPATHIC RETINAL PERIPHLEBITIS; LEUKOCYTE DIFFERENTIAL COUNT; LEUKOPENIA; LIVER FUNCTION TEST; NAUSEA; PRIORITY JOURNAL; RASH; RESPONSE TIME; RETINA DISEASE; SINGLE DRUG DOSE; THROMBOCYTE COUNT; VISUAL ACUITY; VOMITING;

EID: 21744444264     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210501500310     Document Type: Article

References (30)

1. Eales H. Retinal haemorrhage associated with epistaxis and constipation. Brim Med Rev 1880; 9: 262.
2. Eales H. Primary retinal haemorrhage in young men. Ophthalmic Rev 1882; 1: 41.
3. Duke-Elder S, Dobree JH. Primary perivasculitis of the retina: Eales disease. In: Duke Elder S, Perkins EJ, eds. System of Ophthalmology, vol. X. London: Henry Kimpton; 1967: 222-36.
4. Elliot AJ. 30-year observation of patients with Eales disease. Am J Ophthalmol 1975; 80: 404-8.
5. Kimura SJ, Carriker FR, Hogen MJ. Retinal vasculitis with intraocular hemorrhage. Classification and results of special studies. Arch Ophthalmol 1956; 56: 361-5.
6. Cross AG. Vasculitis retinae. Trans Ophthalmol Soc UK 1963; 83: 133.
7. Saxena S, Rajasingh J, Biswas S, Kumar D, Shinohara T, Singh V.K. Cellular response to Retinal S-antigen and inter-photoreceptor retinoid binding protein fragments in patients with Eales disease. Pathobiology 1999; 67: 37-44.
8. Saxena S, Khanna VK, Kumar D, Srivastava P, Seth PK. Enhanced oxidative stress in Eales disease. Ann Ophthalmol 2001; 33: 40-2.
9. Saxena S, Kumar D, Srivastava P, Khanna VK, Seth PK. Low levels of platelet glutathione in Eales disease. Med Sci Res 1999; 42: 125-6.
10. Srivastava P, Saxena S, Khanna VK, Kumar D, Nath R, Seth PK. Raised platelet thiobarbituric acid reacting substances in proliferative Eales disease. Ind J Ophthalmol 2000; 48: 307-10.
11. Saxena S, Khanna VK, Kumar D, Srivastava P, Seth PK. Impaired antioxidant defense mechanism in central Eales disease. Ann Ophthalmol 2004; 36: 29-31.
12. Bhooma V, Sulochana KN, Biswas J, Ramakrishnan S. Eales disease: accumulation of reactive oxygen intermediates and lipid peroxides and decrease of antioxidants causing inflammation, neovascularization and retinal damage. Curr Eye Res 1997; 16: 91-5.
13. Sulochana KN, Biswas J, Ramakrishnan S. Eales disease: increased oxidation and peroxidation products of membrane constituents chiefly lipids and antioxidant enzymes and reduced glutathione in vitreous. Curr Eye Res 1999; 19: 254-9.
14. Swamy-Mruthinti S, Miriam KC, Kumar SK, et al. Immunolocalization and quantification of advanced glycation end products in retinal neovascular membranes and serum: a possible role in ocular neovascularization. Curr Eye Res 2002; 25: 139-45.
15. Saxena S, Kumar D. A new staging system of idiopathic retinal periphlebitis. Eur J Ophthalmol 2004; 14: 236-9.
16. Badrinath SS, Biswas J, Sharma T, Gopal L. Immunophenotyping of inflammatory infiltrates in epiretinal (ERM) and subretinal membrane (SRM) in Eales disease. Invest Ophthalmol Vis Sci 1992; 33 (Suppl): S 857.
17. Saxena S, Kumar D, Kapoor S. Efficacy of oral methotrexate pulsed therapy in Eales disease. Ann Ophthalmol 2000; 31: 60-2.
18. Giannini EH, Brewer E, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. N Engl J Med 1992; 326: 1043-50.
19. Lazar M, Weiner MJ, Leopold IH. Treatment of uveitis with methotrexate. Am J Ophthalmol 1969; 67: 383-7.
20. Shah SS, Lowder CY, Schmitt MA, Wilke WS, Kosmorsky GS, Meisler DM. Low dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992; 99: 1419-23.
21. Foster M, Weiner MJ, Leopold IH. Treatment of uveitis with methotrexate. Am J Ophthalmol 1969; 67: 383-7.
22. Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid associated pan uveitis. Ophthalmology 1999; 106: 111-8.
23. Palmer HE, Stanford MR, Sanders MD, Graham EM. Visual outcome of patients with idiopathic ischemic and non-ischemic retinal vasculitis. Eye 1995; 10: 343-8.
24. Elliot AJ, Harris GS. The present status of the diagnosis and treatment of periphlebitis retinae (Eales disease). Can J Ophthalmol 1969; 4: 117-21.
25. Biswas J, Sharma T, Gopal L, Madhavan HN, Sulochana KN, Ramakrishnan S. Eales disease - an update. Surv Ophthalmol 2002; 47: 197-214.
26. Hemadi R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol 1991; 35: 396-405.
27. Tamesis R, Rodriguez A, Christen W. Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Ophthalmology 1996; 103: 768-76.
28. Meyer PA, Watson PG, Franks W, Dubois P. Pulsed immunosuppressive therapy in the treatment of immunologically induced corneal and scierai disease. Eye 1987; 1: 487-95.
29. Willkens RF, Leonard PA, Clegg DO. Liver histology in patients receiving low dose pulse methotrexate for the treatment of rheumatoid arthritis. Ann Rheum Dis 1990; 49: 591-3.
30. Kaplan MM. Methotrexate hepatotoxicity and the premature reporting of Mark Twain's death, both greatly exaggerated. Hepatology 1990; 12: 784-6.